Ignite Creation Date:
2024-05-06 @ 7:03 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05870748
Status:
RECRUITING
Last Update Posted:
2024-04-19
First Post:
2023-05-12
Brief Title:
REFRaME-O1 A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigators Choice IC Chemotherapy in Women With Ovarian Cancer Including Fallopian Tube or Primary Peritoneal Cancers Expressing FOLR1
Sponsor:
Sutro Biopharma Inc
Organization:
Sutro Biopharma Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-07-12
Start Date Type:
ACTUAL
Primary Completion Date:
2025-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-02
Completion Date Type:
ESTIMATED
First Submit Date:
2023-05-12
First Submit QC Date:
May 12 2023
Study First Post Date:
2023-05-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-27
Last Update Post Date:
2024-04-19
Last Update Post Date Type:
ACTUAL